Safety and efficacy of ciprofol vs. propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial

BACKGROUND: Ciprofol (HSK3486; Haisco Pharmaceutical Group Co., Ltd., Chengdu, China), developed as a novel 2,6-disubstituted phenol derivative showed similar tolerability and efficacy characteristics as propofol when applicated as continuous intravenous infusion for 12 h maintenance sedation in a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongjun, Yu, Xiangyou, Zhu, Duming, Zeng, Jun, Lin, Qinhan, Zang, Bin, Chen, Chuanxi, Liu, Ning, Liu, Xiao, Gao, Wei, Guan, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276409/
https://www.ncbi.nlm.nih.gov/pubmed/34924506
http://dx.doi.org/10.1097/CM9.0000000000001912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276409/
https://www.ncbi.nlm.nih.gov/pubmed/34924506
http://dx.doi.org/10.1097/CM9.0000000000001912

Ejemplares similares